Abstract
An in vitro model for cross-correction of lysosomal storage disorders from genetically modified cells was developed to approximate the physiological conditions needed for gene therapy in vivo. β-Glucuronidase (GUSB)-deficient mucopolysaccharidosis (MPS) type VII (Sly disease) cells were studied to determine the amount and stability of enzyme transfer. Gene transfer by retroviral vectors encoding rat or human GUSB corrected the enzymatic deficiency in cultured MPS VII fibroblasts from humans, dogs, and mice. The vector-transduced cells released GUSB into the culture supernatant in amounts proportional to the amounts of cellular GUSB activity. The activity of the exported GUSB was stable in tissue culture medium for at least two weeks. Uninfected MPS VII target cells incorporated GUSB from the medium when the vector-infected donor cells were separated from the deficient target cells by a fluid-permeable membrane. The high level of GUSB in the cross-corrected target cells decreased rapidly after the enzyme donor cells were removed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.